We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AZN Astrazeneca Plc

0.00 (0.00%)
27 Feb 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 10,254.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
10,262.00 10,266.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations USD 45.81B USD 5.96B USD 3.8415 26.72 159.14B
Last Trade Time Trade Type Trade Size Trade Price Currency
19:34:18 O 276 10,270.105 GBX

Astrazeneca (AZN) Latest News

Astrazeneca (AZN) Discussions and Chat

Astrazeneca (AZN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-02-26 17:30:3010,284.271,324136,163.71O
2024-02-26 17:28:3210,254.92151,538.24O
2024-02-26 17:28:3110,288.004,285440,840.71O
2024-02-26 17:28:1410,283.004411.32O

Astrazeneca (AZN) Top Chat Posts

Top Posts
Posted at 20/2/2024 09:46 by philanderer
Berenberg cuts AstraZeneca price target to 12,000 (12,500) pence - 'buy'
Posted at 12/2/2024 11:11 by 1knocker
Quite a spread of views!

It is important to bear in mind what a commentator's price target means: it is not 'current fair value', but (unless otherwise stated) a price which the commentator at present believes will be hit at some time within the following 12 months, and not necessarily sustained thereafter, still less that there will not be further rises /falls from the price at the date on which the target was stated before that figure is hit, if indeed it is hit.
Posted at 12/2/2024 10:57 by philanderer
Stifel cuts AstraZeneca price target to 12,000 (12,550) pence - 'buy'

Barclays cuts AstraZeneca price target to 12,500 (13,500) pence - 'overweigh

UBS cuts AstraZeneca price target to 9,900 (10,700) pence - 'sell'
Posted at 09/2/2024 14:36 by philanderer
Deutsche Bank cuts AstraZeneca to 'sell' (hold) - price target 9,500 (11,000) pence
Posted at 08/2/2024 16:34 by 1knocker
AZN is still pretty richly priced. I think it should slide a bit more. I may put a limit order in to buy a few more at 93, though that will significantly above my average, currently 58 after a few out and back in round trips a few years back.

AZN does not pay much of a dividend, and I see no catalyst to move the price north at present, so in this uncertain market I shall probably put in my order at 90 and be patient.
Posted at 16/1/2024 11:00 by steeplejack
For the last six months,AZN has traded fairly predictably between £100 to £110.
Posted at 15/12/2023 15:44 by smcni1968
Hopefully a better year for the share price in 2024.
Posted at 05/12/2023 17:50 by turvart
AZN now well below the 200 & 50 day moving average, the 200 day MA is approx 11000 area so this is a steal IMO with all the future developments in phase 11 & 111 trials. One aspect I also like is the fact AZN do not stand still and get complacent the company is always striving to get bigger and make regular acquisitions.

AZN was my very first stock I purchased when I was a complete newbie back in 2001 and I paid £17.50 a share back then, look at the growth of this immense stock of which I'm sure will get to £130 by the end of 2024 IMO, AZN was in my portfolio in 2001 at 1750 and still are and has been my best performing stock, just wished I'd have bought more and left them alone re-investing the dividends along the way.

Strong buy IMO.
Posted at 17/11/2023 07:29 by mr euro
I don't own AZ so have no interest.


Not sure how a sale would effect the share price, be it a sale or standalone listing out of HK? One would assume this would be positive.
Posted at 05/7/2023 09:06 by philanderer
Berenberg lowers AstraZeneca target price

A lung cancer treatment from AstraZeneca (AZN) failed to meet high investor expectations but the share price drop is ‘overdone̵7;, says Berenberg.

Analyst Luisa Hector reiterated her ‘buy’ recommendation but lowered her target price slightly from £135 to £133 on the Citywire Elite Companies AAA-rated stock, which rose 2.2%, or 228p, to £106.02 on Tuesday.

The pharmaceutical giant, along with its partner Daiichi Sankyo, announced positive progression-free survival headline data for their lung cancer treatment.

‘The absence of more positive language in the press release, such as “clinically meaningful”, and the occurrence of some fatal interstitial lung disease events missed high investor expectations, resulting in AstraZeneca’s share price falling by 8%,’ said Hector.

She said the future of the drug relies on further testing, which is expected in the next six months.

‘We lower our price target to £133… a much smaller reduction than the share price move of 900p. We think the stock reaction is overdone given the overall strength of AstraZeneca’s pipeline,’ she said.
Astrazeneca share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |